MorphoSys AG
MORNASDAQHealthcare
$18.96
+$0.45(+2.43%)
Market Cap$2.9B
P/E Ratio—
52W High$19.5
52W Low$4.185
MorphoSys AG (MOR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MOR · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 29, 2024EPS Actual
-$0.59
Est. -$1.33 · +55.6%
Revenue
—
Est. $0.06B
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 29, 2024
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
MOR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2024 | Aug 29, 2024 | -$1.33 | -$0.59 | +55.6% | — | $0.06B | — |
| ▼ Q2 FY2024 | Apr 29, 2024 | -$1.20 | -$2.10 | -75.0% | $0.03B | $0.07B | -57.5% |
| ▲ Q1 FY2024 | Mar 13, 2024 | $0.08 | $0.36 | +350.0% | $0.06B | $0.06B | +1.4% |
| ▲ Q4 FY2023 | Nov 15, 2023 | -$1.72 | -$0.87 | +49.4% | $0.07B | $0.06B | +9.0% |
| ▲ Q3 FY2023 | Aug 9, 2023 | -$1.70 | -$0.54 | +68.2% | $0.06B | $0.06B | -2.2% |
| ▲ Q2 FY2023 | May 3, 2023 | -$0.48 | -$0.33 | +31.3% | $0.07B | $0.05B | +48.8% |
| ▲ Q1 FY2023 | Mar 15, 2023 | -$0.42 | $2.41 | +673.8% | $0.09B | $0.05B | +63.7% |
| ▼ Q4 FY2022 | Nov 16, 2022 | -$0.39 | -$0.90 | -130.8% | $0.09B | $0.06B | +64.6% |
Q3 FY2024
Aug 29, 2024Beat
EPS Actual
-$0.59
EPS Est.
-$1.33
EPS Surpr.
+55.6%
Revenue
—
Q2 FY2024
Apr 29, 2024Miss
EPS Actual
-$2.10
EPS Est.
-$1.20
EPS Surpr.
-75.0%
Revenue
$0.03B
Q1 FY2024
Mar 13, 2024Beat
EPS Actual
$0.36
EPS Est.
$0.08
EPS Surpr.
+350.0%
Revenue
$0.06B
Q4 FY2023
Nov 15, 2023Beat
EPS Actual
-$0.87
EPS Est.
-$1.72
EPS Surpr.
+49.4%
Revenue
$0.07B
Q3 FY2023
Aug 9, 2023Beat
EPS Actual
-$0.54
EPS Est.
-$1.70
EPS Surpr.
+68.2%
Revenue
$0.06B
Q2 FY2023
May 3, 2023Beat
EPS Actual
-$0.33
EPS Est.
-$0.48
EPS Surpr.
+31.3%
Revenue
$0.07B
Q1 FY2023
Mar 15, 2023Beat
EPS Actual
$2.41
EPS Est.
-$0.42
EPS Surpr.
+673.8%
Revenue
$0.09B
Q4 FY2022
Nov 16, 2022Miss
EPS Actual
-$0.90
EPS Est.
-$0.39
EPS Surpr.
-130.8%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2025 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q4 FY2024 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q3 FY2024 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Q2 FY2024 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Q1 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2023 | $-0.46 | $-0.46 | $-0.46 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2024 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.1B | $0.1B | $0.1B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2024 | Aug 29, 2024 | +55.6% | $18.96 | — | — |
| ▼ Q2 FY2024 | Apr 29, 2024 | -75.0% | $18.04 | $17.36 | -3.77% |
| ▲ Q1 FY2024 | Mar 13, 2024 | +350.0% | $18.17 | $18.04 | -0.72% |
| ▲ Q4 FY2023 | Nov 15, 2023 | +49.4% | $7.48 | $6.95 | -7.09% |
| ▲ Q3 FY2023 | Aug 9, 2023 | +68.2% | $7.51 | $7.50 | -0.13% |
| ▲ Q2 FY2023 | May 3, 2023 | +31.3% | $5.22 | $5.15 | -1.34% |
| ▲ Q1 FY2023 | Mar 15, 2023 | +673.8% | $3.97 | $3.74 | -5.79% |
| ▼ Q4 FY2022 | Nov 16, 2022 | -130.8% | $3.93 | $3.86 | -1.78% |
Q3 FY2024—
Report Date
Aug 29, 2024
EPS Beat/Miss
+55.6%
Price Before
$18.96
Price After
—
Q2 FY2024-3.77%
Report Date
Apr 29, 2024
EPS Beat/Miss
-75.0%
Price Before
$18.04
Price After
$17.36
Q1 FY2024-0.72%
Report Date
Mar 13, 2024
EPS Beat/Miss
+350.0%
Price Before
$18.17
Price After
$18.04
Q4 FY2023-7.09%
Report Date
Nov 15, 2023
EPS Beat/Miss
+49.4%
Price Before
$7.48
Price After
$6.95
Q3 FY2023-0.13%
Report Date
Aug 9, 2023
EPS Beat/Miss
+68.2%
Price Before
$7.51
Price After
$7.50
Q2 FY2023-1.34%
Report Date
May 3, 2023
EPS Beat/Miss
+31.3%
Price Before
$5.22
Price After
$5.15
Q1 FY2023-5.79%
Report Date
Mar 15, 2023
EPS Beat/Miss
+673.8%
Price Before
$3.97
Price After
$3.74
Q4 FY2022-1.78%
Report Date
Nov 16, 2022
EPS Beat/Miss
-130.8%
Price Before
$3.93
Price After
$3.86
Avg Beat Reaction-3.01%
Avg Miss Reaction-2.77%
Beat Rate6 / 8 quarters
Largest Move-7.09% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MOR ends December
MorphoSys AG (MOR) most recently reported earnings on August 29, 2024 for Q3 FY2024, posting EPS of $-0.59 — beating the analyst consensus of $-1.33 by +55.6%. The next MOR earnings date is expected around September 1, 2026.
Each quarter, investors track MOR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MOR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MOR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MOR earnings · 5 questionsMorphoSys AG's next earnings report is expected around September 1, 2026. MOR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MOR historically reports after market close (AMC).
MOR earnings datewhen is MOR earningsMOR next earnings datewhen does MOR report earningsMOR earnings calendar
▸ Source: FMP · MorphoSys AG SEC filings · US GAAP · MorphoSys AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026